University of Bielefeld, NIOMECH, Universitatsstr. 25, 33-615 Bielefeld, Germany
Bibliografia
ADIS INTERNATIONAL LIMITED. 2005. Glufosfamide: Beta-D-Gle- IPM, D-19575. Drug R&D 6: 49-52.
ENGEL, J., T. KLENNER, U. NIEMEYER, G. PETER, J. POHL, M. SCHüBLER, A. SCHUPKE, A. Voss, and M. WIESSLER. 2000. Glufosfamide. Drug. Future 25: 791-794.
LIANG, J., M. HUANG, W. DUAN, X.Q. YU, and S. ZHOU. 2007. Design of new oxazaphosphorine anticancer drugs. Curr. Pharm. Design. 13: 963-978.
MAZUR L., M. OPYDO-CHANEK, H.D. HALICKA, Z. DARŻYNKIEWICZ, and U. NIEMEYER. 2007. Induction of programmed cell death by glufosfamide. Cancer Therapeutics: The Road Ahead. A Capri Science Conference, Capri, Italy, 52. MAZUR, L., M. STOJAK, M. OPYDO-CHANEK, and U. NIEMEYER. 2009. Mitotic catastrophe induction in U937 cells by oxazaphosphorines. Acta Biol. Cracov. Series Zoologica 51: 17-22.
MAZUR, L., M. OPYDO-CHANEK, M. STOJAK, J. BARAN, and U. NIEMEYER. 2010. Induction of DNA breakage in U937 cells by oxazaphosphorines. Folia biol. (Kraków) 58: 15-20.
OPYDO-CHANEKM., L. MAZUR, M. STOJAK, and U. NIEMEYER. 2010. Comparative effects of new generation oxazaphosphorines on cancer cell death. 6th Swiss Apoptosis Meeting, Bern, Switherland, 46.
Ross, D.W. 1981a. The nature of unbalanced cell growth caused by cytotoxic agents. Virchows Archiv B Cell Pathol. Zell-Pathologie 37: 225-235.
Ross, D.W. 1981b. Volume increase in L5222 leukaemic cells following chemotherapy: Manifestation of leukaemic cell damage. Leukemia Res. 5: 73-80.
SEKER, H., B. BERTRAM, A. BURKLE, B. KAINA, J. POHL, H. KOEPSELL, and M. WIESSLER. 2000. Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumor therapeutic agent. Brit. J. Cancer 82: 629-634.
ZHANG, J., Q. TIAN, S. YUNG CHAN, S. CHUEN LI, S. ZHOU, W. DUAN, and Y.Z. ZHU. 2005a. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug. Metab. Rev. 37: 611-703.
ZHANG, J., Q. TIAN, S. YUNG CHAN, W. DUAN, and S. ZHOU. 2005b. Insight into oxazaphosphorine resistance and possible approaches to its circumvention. Drug Resist. Uptate. 8: 271-297.